- Home
- OMI vs SLN Comparison
OMI vs SLN Comparison
Compare OMI & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMI
- SLN
- Stock Information
- Founded
- OMI 1882
- SLN 1994
- Country
- OMI United States
- SLN United Kingdom
- Employees
- OMI N/A
- SLN N/A
- Industry
- OMI Medical Specialities
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- OMI Health Care
- SLN Health Care
- Exchange
- OMI Nasdaq
- SLN Nasdaq
- Market Cap
- OMI 415.6M
- SLN 345.3M
- IPO Year
- OMI N/A
- SLN N/A
- Fundamental
- Price
- OMI $2.77
- SLN $6.67
- Analyst Decision
- OMI Hold
- SLN Buy
- Analyst Count
- OMI 6
- SLN 6
- Target Price
- OMI $6.46
- SLN $39.67
- AVG Volume (30 Days)
- OMI 2.3M
- SLN 212.8K
- Earning Date
- OMI 10-30-2025
- SLN 11-06-2025
- Dividend Yield
- OMI N/A
- SLN N/A
- EPS Growth
- OMI N/A
- SLN N/A
- EPS
- OMI N/A
- SLN N/A
- Revenue
- OMI $10,768,859,000.00
- SLN $25,830,000.00
- Revenue This Year
- OMI N/A
- SLN N/A
- Revenue Next Year
- OMI N/A
- SLN N/A
- P/E Ratio
- OMI N/A
- SLN N/A
- Revenue Growth
- OMI 132.03
- SLN 40.39
- 52 Week Low
- OMI $2.58
- SLN $1.97
- 52 Week High
- OMI $15.54
- SLN $8.88
- Technical
- Relative Strength Index (RSI)
- OMI 29.67
- SLN 55.39
- Support Level
- OMI $2.75
- SLN $5.91
- Resistance Level
- OMI $2.88
- SLN $6.62
- Average True Range (ATR)
- OMI 0.19
- SLN 0.51
- MACD
- OMI 0.03
- SLN -0.05
- Stochastic Oscillator
- OMI 25.87
- SLN 81.25
About OMI Owens & Minor Inc.
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.